苯那普利、纈沙坦對(duì)2型糖尿病腎病早期患者尿MCP-1的影響.pdf

1、Objective To study the effects of angiotension Ⅱ convertase inhibitor and angiotension Ⅱ receptor angiotension on urinary monocyte chemoattractant protein-1(MCP-1) as well as their clinic significance in human early d

2、iabetic nephropathy. Methods 39cases of patients with type2 diabetes and diabetic nephropathy (urinary albumin excretion rate (UAER) is 20-200μg/min) and without cardopathy, liverish and nephropathy, were divided into

3、 3 groups by random. Group 1 (n=14) was treated with benazepril (10 mg/d). Group 2 (n=13)was treated with valsartant (80 mg/d). And group 3was treated with combination of benazepril and valsartant. Before treatment and a

4、fter 8, 12 weeks of posttreatment, urnary MCP-1 levels were measured by enzyme-linked immunosorbent assay (ELISA) and UAER were measured by radioimrnunoassay. Then comparation of pretreatment and posttreatment was done b

5、etween the three groups and between individuals in each group.Results (1) After 8 weeks' therapy, there was no significant differences (P＞0.05) between the MCP-1 and UAER decrease rate of1 group and that of 2group.

6、The urinary MCP-1 and UAER decrease rates of three treatment groups all have extremely significant increases (p＜0.01) in contrast with pretreatment. After 12 weeks' therapy, there was significant differences (P＜

7、0.05) between the MCP-1 and UAER decrease rate of 1 group and that of 2group. The urinary MCP-1 and UAER decrease rates of three treatment groups all have extremely significant increases(p＜0.01) in contrast with pretrea

8、tment. (2) After 8 ,12 weeks' therapy with benazepril and valsartant.,there were positive correlation on decent rate between urinary MCP-1 levels and UAER in human early diabetic nephropathy.Conclusion (1) RAS s

9、ystem was blocked by in the type 2 diabetic patients intercurrent with nephropathy so that urinary MCP-1 level was reduced. These results also showed that combined medicament treatment was better than single medicament t